A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas
Phase of Trial: Phase I/II
Latest Information Update: 24 May 2018
At a glance
- Drugs TG 01 Targovax (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Targovax
- 24 May 2018 According to a Targovax ASA media release, status changed from active, no longer recruiting to completed.
- 24 May 2018 Results presented in a Targovax ASA media release.
- 15 Feb 2018 According to a Targovax media release, complete trial results are expected in the first half of 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History